Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of ABSK061 in Healthy Adults
NCT07007546Phase 1Completed
- Sponsor
- Abbisko Therapeutics
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lavengratinib in solid tumor (3 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration, Minimum Observed Plasma Concentration and 6 more. Started May 2025; status: completed.
02
Drugs
lavengratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07007546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007546.